Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Should we screen for prostate cancer?]

P Mangin1, L Cormier, A Valéri

  • 1Service d'Urologie, CHU Nancy-Brabois.

Annales D'Urologie
|May 26, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phase I Clinical Study of DOC1021 (dubodencel) for Adjuvant Immunotherapy of Glioblastoma.

medRxiv : the preprint server for health sciences·2026
Same author

Rational optimization of D3R/GSK-3β dual target-directed ligands as potential treatment for bipolar disorder: Design, synthesis, X-ray crystallography, molecular dynamics simulations, in vitro ADME, and in vivo pharmacokinetic studies.

European journal of medicinal chemistry·2025
Same author

Which protocol for prostate biopsies in patients with a positive MRI? Interest of systematic biopsies by sectors.

Prostate cancer and prostatic diseases·2023
Same author

Direct comparison between Grade Group assessed on systematic and MRI/ultrasound fusion targeted biopsies correlated to the radical prostatectomy specimens in patients with prostate cancer.

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2023
Same author

[The impact of restaging transurethral resection on recurrence and progression free survival in patients with T1 high grade bladder cancer].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2023
Same author

[Morbidity of extended pelvic lymphadenectomy during robot-assisted laparoscopic prostatectomy for localized cancer prostate].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2022
Same journal

Prostate cancer at the 2007 ASCO meeting: an urologist's perspective.

Annales d'urologie·2008
Same journal

[Surgical treatment of ureteropyelic junction stenosis using robotic-assisted laparoscopy].

Annales d'urologie·2008
Same journal

[Robotic-assisted laparoscopy: general principles].

Annales d'urologie·2008
Same journal

[De novo tumours of renal transplants].

Annales d'urologie·2008
Same journal

[Immunosuppression in kidney transplantation].

Annales d'urologie·2008
Same journal

[Surgical complications in kidney transplantation].

Annales d'urologie·2008
See all related articles

Prostate cancer screening is controversial, with recommendations varying by age and family history. Future screening may involve genetic testing for high-risk individuals and earlier, later screening for others.

Area of Science:

  • Urology
  • Oncology
  • Public Health

Context:

  • The debate on prostate cancer screening justification spans a decade.
  • Driven by advancements in diagnostic tools like prostate-specific antigen (PSA) testing, an aging population, and economic considerations.
  • Current guidelines address screening for different age groups and risk factors.

Purpose:

  • To evaluate the justification and optimal timing for prostate cancer screening.
  • To analyze the medico-economic aspects influencing screening decisions.
  • To propose future directions for prostate cancer screening strategies.

Summary:

  • Screening is not recommended before age 50, except for high-risk families starting at 40.
  • Screening is not advised after age 70, unless life expectancy exceeds 10 years.

Related Experiment Videos

  • Screening between 50-70 presents a conflict between individual medical benefit and community economic cost.

    • Impact:

    • Informs clinical practice regarding age-appropriate prostate cancer screening.
    • Highlights the economic challenges in widespread screening programs.
    • Suggests a future shift towards personalized screening based on genetic predisposition and improved diagnostics.